Telomir signs binding LOI to acquire TELI, consolidating worldwide rights to Telomir-1

Telomir Pharmaceuticals, Inc.

Acquires all TELI shares via stock-for-stock exchange; exchange ratio based on third-party valuation.
Certain TELI shareholders to contribute $5M cash: $1M at closing, $2M on FDA IND acceptance, $2M on Phase 1/2 start.
Transaction consolidates global IP rights to Telomir-1, an oral epigenetic therapy for cancer and aging.
No TELI leadership retained post-closing; TELI shareholders subject to six-month lock-up.
Closing subject to due diligence, board/stockholder approvals, regulatory clearances within 90 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.